The MPA focuses on eyelash growth serum

The Swedish Medical Products Agency is concerned by the fact that eyelash growth products may contain prohibited substances known as prostaglandin analogues. This type of substance may give rise to serious side effects and there is a keen interest among consumers to buy and use this type of products. Consequently, the MPA will take a broader approach during 2013, by mapping the Swedish market, acquiring and analysing relevant products and communicating analysis results.

Source: MPA RSS news - - March 5, 2013 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news